var data={"title":"Bivalirudin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bivalirudin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5748?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bivalirudin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bivalirudin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141778\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Angiomax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141779\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Angiomax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141795\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Direct Thrombin Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141781\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac surgery in patients with acute or subacute heparin-induced thrombocytopenia, urgent surgery required (off-label use) (Linkins 2012): </b> IV: Intraoperative:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Off-pump:</b></i> Initial bolus: 0.75 mg/kg, followed by continuous infusion 1.75 mg/kg/hour to maintain ACT &gt;300 seconds (Dyke 2007). If patient needs to go on-pump, some have recommended an additional 0.25 mg/kg bolus and increasing the infusion rate to 2.5 mg/kg/hour (Angiomax Canadian product labeling 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>On-pump:</b></i>Initial bolus: 1 mg/kg, followed by continuous infusion 2.5 mg/kg/hour; 50 mg bolus added to priming solution of cardiopulmonary bypass (CPB) circuit. Additional boluses of 0.1 to 0.5 mg/kg may be given to maintain ACT &gt;2.5 times baseline ACT. Discontinue infusion 10 to 15 minutes prior to weaning from CPB (Salter 2016). <b>Note:</b> Special maneuvers needed to prevent stasis and consequent clotting within CPB circuit during or after surgery (Koster 2007). After completion of CPB, provision to allow recirculation of the circuit may be done by administering 50 mg <b>into the circuit</b> followed by a continuous infusion of 50 mg/hour <b>into the bypass circuit; </b>continue infusion until it is evident the patient will not require an urgent return to CPB. If separation from circuit does not occur within 20 minutes of stopping infusion, redose patient with 0.5 mg/kg and restart infusion at 2.5 mg/kg/hour (Salter 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin-induced thrombocytopenia (HIT) (off-label use):</b> IV: Initial dose: 0.15 to 0.2 mg/kg/hour; adjust to aPTT 1.5 to 2.5 times baseline value (ACCP [Linkins 2012]). <b>Note:</b> Although the use of bivalirudin is not a currently recommended treatment for HIT due to insufficient evidence, the American College of Chest Physicians recommends overlapping administration of warfarin for a minimum of 5 days until INR is within target range; recheck INR after the non-heparin anticoagulant effect has dissipated (ACCP [Linkins 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ischemic heart disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute coronary syndromes: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>In addition to aspirin, concomitant administration of a P2Y12 inhibitor is also recommended for patients undergoing PCI (ACCF/AHA/SCAI [Levine 2011]). If clinically indicated, provisional glycoprotein (GP) IIb/IIIa inhibition (eg, abciximab, eptifibatide, tirofiban) may be concomitantly administered during percutaneous coronary intervention (PCI), but may be associated with more bleeding (Stone 2006). Contemporary practice of ACS includes more frequent use of potent P2Y12 inhibitors (eg, prasugrel, ticagrelor, cangrelor), less use of GP IIb/IIIa inhibitors, and radial artery rather than femoral artery access. For patients receiving a potent P2Y12 inhibitor and radial artery access, bivalirudin compared to heparin alone, with no planned use of a GP IIb/IIIa inhibitor in either group, resulted in similar rates of bleeding, all-cause mortality, MI, and stent thrombosis (Erlinge 2017). Some experts prefer heparin alone over bivalirudin due to decreased cost and similar outcomes although bivalirudin is still a reasonable option when clopidogrel is used or when femoral artery access is utilized (Cutlip 2018; Lincoff 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Non-ST-elevation acute coronary syndrome (moderate-high risk) undergoing early invasive strategy (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>If initiating bivalirudin <b>during</b> PCI: </i>IV: Initial: 0.75 mg/kg bolus prior to procedure, followed by 1.75 mg/kg/hour for the duration of the procedure. During the procedure, may measure ACT 5 minutes after bolus dose and administer an additional bolus of 0.3 mg/kg if necessary. After the procedure is complete, consider continuation of the infusion at 1.75 mg/kg/hour for up to 4 hours if needed. If continued anticoagulation is needed after the initial 4-hour post-procedure infusion, the infusion may be continued at 0.2 mg/kg/hour for up to an additional 20 hours. <b>Note:</b> If patient received unfractionated heparin (UFH) prior to procedure, wait 30 minutes before initiating bivalirudin (ACC/AHA [Amsterdam 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>If initiating bivalirudin <b>prior to</b> PCI or diagnostic angiography:</i> IV: Initial: Administer an initial 0.1 mg/kg bolus, followed by 0.25 mg/kg/hour; continue until diagnostic angiography or PCI. Once PCI is determined to be necessary, give an additional bolus of 0.5 mg/kg and increase infusion rate to 1.75 mg/kg/hour during PCI (ACC/AHA [Amersterdam 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>ST-elevation myocardial infarction undergoing primary PCI (off-label use)</b>: IV: Initial: 0.75 mg/kg bolus prior to the procedure, followed by 1.75 mg/kg/hour for the duration of procedure (ACCF/AHA [O'Gara 2013]; Stone 2008). During the procedure, may measure ACT 5 minutes after bolus dose and administer an additional bolus of 0.3 mg/kg if necessary. After the procedure is complete, consider continuation of the infusion at 1.75 mg/kg/hour for up to 4 hours to mitigate risk of stent thrombosis. If continued anticoagulation is needed after the initial 4-hour post-procedure infusion, the infusion may be continued at 0.2 mg/kg/hour for up to an additional 20 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>If patient received unfractionated heparin (UFH) prior to procedure and bivalirudin is the desired anticoagulant:</i> Discontinue heparin if infusing; without measurement of ACT, may initiate bivalirudin &ge;30 minutes after the last UFH bolus but before PCI occurs (Stone 2008). Switching patients from UFH to bivalirudin has been shown to be safe compared to continuing with UFH and as needed glycoprotein IIb/IIIa inhibition; median time from prerandomization UFH bolus to bivalirudin administration within the HORIZONS-AMI trial was 64 &plusmn; 61 minutes (Dangas 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Percutaneous coronary intervention or percutaneous transluminal coronary angioplasty with or without heparin induced thrombocytopenia:</b> IV: Initial: 0.75 mg/kg bolus immediately prior to procedure, followed immediately by 1.75 mg/kg/hour for the duration of procedure. During the procedure, may determine ACT 5 minutes after bolus dose and administer an additional bolus of 0.3 mg/kg if necessary. After the procedure, may continue the infusion at 1.75 mg/kg/hour for up to 4 hours if needed. If continued anticoagulation is needed after the initial 4-hour postprocedure infusion, the infusion may be continued at 0.2 mg/kg/hour for up to an additional 20 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141782\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. No dosage adjustment is needed in elderly patients with normal renal function. Puncture site hemorrhage and catheterization site hemorrhage were seen in more patients &ge;65 years of age than in patients &lt;65 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141783\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Initial bolus dose remains unchanged. Infusion dose should be reduced based on degree of renal impairment. Monitor activated coagulation time (ACT) or aPTT depending on indication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> For use in PCI:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Decrease infusion rate to 1 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis-dependent patients (off dialysis during administration): Decrease infusion rate to 0.25 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>For use in HIT (off-label use):</b> The following dose ranges have been observed in small retrospective observational studies (Kiser 2006; Kiser 2008; Tsu 2011). Of note, critically-ill patients comprised a significant proportion of patients in these observational studies. The following dose recommendations are based on the mean dose achieving aPTT goal within these studies; overlaps may exist; <b>Note:</b> The Cockcroft-Gault equation was used in all studies to define creatinine clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;60 mL/minute: 0.13 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 60 mL/minute: 0.08 to 0.1 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: 0.04 to 0.05 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD): 0.07 mg/kg/hour (Tsu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CRRT (eg, CVVH or CVVHDF): 0.03 to 0.07 mg/kg/hour (Kiser 2006; Tsu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sustained low-efficiency daily diafiltration (SLEDD): 0.09 mg/kg/hour (Tsu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemodialysis:</b> Dialyzable: Yes; ~25% over 4 hours (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141784\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary (Seybert 2006). In patients treated for HIT (off-label use), patients with hepatic impairment required slightly lower doses compared to previous reports for patients with normal hepatic function; however, the lower doses may have been required due to critical illness instead of hepatic impairment (Kiser 2006). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141758\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Angiomax: 250 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141744\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141760\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For IV administration only. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471292\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 250 mg in 500 mL (concentration: 0.5 mg/mL) <b>or</b> 250 mg in 50 mL (concentration: 5 mg/mL) of D<sub>5</sub>W or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141759\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention:</b> Anticoagulant used in conjunction with aspirin with provisional glycoprotein IIb/IIIa inhibitor as described in the REPLACE-2 trial in patients undergoing percutaneous coronary intervention (PCI) (see <b>Note</b>); used in conjunction with aspirin for patients undergoing PCI with (or at risk of) heparin-induced thrombocytopenia (HIT) / thrombosis syndrome (HITTS). <b>Note:</b> Patients requiring immediate catheter-based reperfusion for STEMI were excluded from the REPLACE-2 trial (Lincoff 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous transluminal coronary angioplasty:</b> Anticoagulant used in conjunction with aspirin for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Safety and effectiveness have not been established in patients with acute coronary syndromes who are not undergoing PTCA or PCI.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475242\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cardiac Surgery (with heparin induced thrombocytopenia/thrombosis syndrome [HIT/TS]); Heparin-induced thrombocytopenia, complicated by thrombosis; Non-ST-elevation acute coronary syndrome (NSTE-ACS) (moderate-high risk) undergoing early invasive strategy; ST-elevation myocardial infarction (STEMI) undergoing primary PCI</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174519\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141750\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all anticoagulants, bleeding is the major adverse effect of bivalirudin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation, concurrent use of a glycoprotein IIb/IIIa inhibitor, and patient susceptibility. Additional adverse effects are often related to idiosyncratic reactions, and the frequency is difficult to estimate. Adverse reactions reported were generally less than those seen with heparin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (&le;15%), headache (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Minor hemorrhage (Protocol defined: 14%; heparin 26%; TIMI defined: 1%; heparin 3% [Lincoff, 2003])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (9% to 42%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (6%), bradycardia (5%), angina pectoris (&le;5%), thrombosis (1%; &lt;4 hours, in patients with STEMI undergoing primary PCI)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (7%), anxiety (6%), nervousness (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (&le;6%), abdominal pain (5%), dyspepsia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pelvic pain (6%), urinary retention (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Major hemorrhage (Protocol defined: 2% to 4%; heparin 4% to 9%; TIMI defined: 0.6%; heparin 0.9%; transfusion required: 1% to 2%; heparin 2% to 6% [Lincoff, 2003])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cardiac tamponade, cerebral ischemia, confusion, facial paralysis, hemorrhage, hypersensitivity reaction (including anaphylaxis), increased INR, increased susceptibility to infection, intracranial hemorrhage, oliguria, pulmonary edema, pulmonary hemorrhage, renal failure, retroperitoneal hemorrhage, sepsis, syncope, thrombocytopenia, vascular disease, venous thrombosis (during PCI, including intracoronary brachytherapy), ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141763\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bivalirudin or any component of the formulation; active major bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Major blood clotting disorders; acute gastric or duodenal ulcer; cerebral hemorrhage; severe cerebrospinal trauma; bacterial endocarditis; severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; proximal use of spinal/epidural anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141748\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acute stent thrombosis: In patients with STEMI undergoing PCI, acute stent thrombosis (some fatal) occurring within 4 hours of the procedure was observed at a greater frequency as compared to those treated with heparin. Patients should remain for at least 24 hours in a facility capable of managing ischemic complications; monitor for signs and symptoms consistent with myocardial ischemia. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: The most common complication is bleeding. Certain patients are at increased risk of bleeding; risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; recent puncture of large vessels or organ biopsy; recent CVA, stroke, intracerebral surgery, or other neuraxial procedure; severe uncontrolled hypertension; renal impairment; recent major surgery; recent major bleeding (intracranial, GI, intraocular, or pulmonary). Monitor for signs and symptoms of bleeding. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombus formation: Increased risk of intracoronary thrombus formation (some fatal, as reported by the manufacturer) has been reported with use in gamma brachytherapy even with the use of higher doses as compared to doses used for beta radiation (Kuchulakanti 2005). If used during brachytherapy, maintain meticulous catheter technique with frequent aspiration and flushing while minimizing conditions of stasis within the catheter or vessels. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction required. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298872\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141752\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8792&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141754\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141766\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Bivalirudin is used in conjunction with aspirin, which may lead to maternal or fetal adverse effects, especially during the third trimester. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16248962\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bivalirudin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering bivalirudin to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141756\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Depends upon indication for use of bivalirudin: ACT or aPTT </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141747\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bivalirudin acts as a specific and reversible direct thrombin inhibitor; it binds to the catalytic and anionic exosite of both circulating and clot-bound thrombin. Catalytic binding site occupation functionally inhibits coagulant effects by preventing thrombin-mediated cleavage of fibrinogen to fibrin monomers, and activation of factors V, VIII, and XIII. Shows linear dose- and concentration-dependent prolongation of ACT, aPTT, PT, and TT.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141762\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Coagulation times return to baseline ~1 hour following discontinuation of infusion </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 0.2 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: Does not bind other than thrombin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Blood proteases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Normal renal function (CrCl &ge;90 mL/minute): 25 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe renal impairment (CrCl 10 to 29 mL/minute): 57 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialysis-dependent patients (off dialysis): 3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (20%), proteolytic cleavage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323020\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Angiomax Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $1,149.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Bivalirudin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $528.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141767\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amuprux (AR);</li>\n      <li>Angiodin (BD);</li>\n      <li>Angiomax (AR, AU, CL, IL, IN, NZ);</li>\n      <li>Angiox (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IS, IT, LT, LU, MT, NL, PL, PT, RO, RU, SA, SE, SI, SK, TR);</li>\n      <li>Bivaflo (IN);</li>\n      <li>Bivasave (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allie DE, Lirtzman MD, Wyatt CH, et al, &ldquo;Bivalirudin as a Foundation Anticoagulant in Peripheral Vascular Disease: A Safe and Feasible Alternative for Renal and Iliac Interventions,&quot; <i>J Invasive Cardiol</i>, 2003, 15(6):334-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12777673/pubmed\" target=\"_blank\" id=\"12777673\">12777673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiomax (bivalirudin) [prescribing information]. Parsippany, NJ: The Medicines Company; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiomax (bivalirudin) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc.; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, &ldquo;Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?&rdquo; <i>JAMA</i>, 2003, 289:903-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12588276/pubmed\" target=\"_blank\" id=\"12588276\">12588276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aggarwal A, Sobel BE, and Schneider DJ, &ldquo;Decreased Platelet Reactivity in Blood Anticoagulated With Bivalirudin or Enoxaparin Compared With Unfractionated Heparin: Implications for Coronary Intervention,&rdquo; <i>J Thromb Thrombolysis</i>, 2002, 13:161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12355033/pubmed\" target=\"_blank\" id=\"12355033\">12355033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bittl JA, Chaitman BR, Feit F, et al, &ldquo;Bivalirudin Versus Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina: Final Report Reanalysis of the Bivalirudin Angioplasty Study,&rdquo; <i>Am Heart J</i>, 2001, 142:952-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/11717596/pubmed\" target=\"_blank\" id=\"11717596\">11717596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bittl JA, Strony J, Brinker JA, et al, &ldquo;Treatment With Bivalirudin (Hirulog) as Compared With Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina. Hirulog Angioplasty Study Investigators,&rdquo; <i>N Engl J Med</i>, 1995, 333(12):764-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/7643883/pubmed\" target=\"_blank\" id=\"7643883\">7643883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cutlip, D, Lincoff AM. Anticoagulant therapy in non-ST elevation acute coronary syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 26, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Dougherty JA, Nguyen PH, et al, &ldquo;Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations,&rdquo; <i>Pharmacotherapy</i>, 2007, 27(4):564-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17381384/pubmed\" target=\"_blank\" id=\"17381384\">17381384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16553503\"></a>Dang CH, Durkalski VL, and Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. <i>Pharmacotherapy</i>. 2006;26(4):461-468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16553503/pubmed\" target=\"_blank\" id=\"16553503\">16553503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dangas GD, Mehran R, Nikolsky E, et al, &ldquo;Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-SWITCH Analysis,&rdquo; <i>J Am Coll Cardiol</i>, 2001, 57(23):2309-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/21636031/pubmed\" target=\"_blank\" id=\"21636031\">21636031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis Z, Anderson R, Short D, et al, &ldquo;Favorable Outcome With Bivalirudin Anticoagulation During Cardiopulmonary Bypass,&rdquo; <i>Ann Thorac Surg</i>, 2003, 75(1):264-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12537226/pubmed\" target=\"_blank\" id=\"12537226\">12537226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17720385\"></a>Dyke CM, Aldea G, Koster A, et al, &ldquo;Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies,&rdquo; <i>Ann Thorac Surg</i>, 2007, 84(3):836-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17720385/pubmed\" target=\"_blank\" id=\"17720385\">17720385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dyke CM, Smedira NG, Koster A, et al, &ldquo;A Comparison of Bivalirudin to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: The EVOLUTION-ON Study,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 2006, 131(3):533-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16515902/pubmed\" target=\"_blank\" id=\"16515902\">16515902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28844201\"></a>Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. <i>N Engl J Med.</i> 2017;377:1132-1142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/28844201/pubmed\" target=\"_blank\" id=\"28844201\">28844201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs J and Cannon CP, &ldquo;Hirulog in the Treatment of Unstable Angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial,&rdquo; <i>Circulation</i>, 1995, 92(4):727-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/7641350/pubmed\" target=\"_blank\" id=\"7641350\">7641350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25775052\"></a>Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The BRIGHT randomized clinical trial. <i>JAMA.</i> 2015;313(13):1336-1346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25775052/pubmed\" target=\"_blank\" id=\"25775052\">25775052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiser TH and Fish DN, &ldquo;Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically Ill Patients With Hepatic and/or Renal Dysfunction,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(4):452-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16553502/pubmed\" target=\"_blank\" id=\"16553502\">16553502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18752382\"></a>Kiser TH, Burch JC, Klem PM, et al, &ldquo;Safety, Efficacy, and Dosing Requirements of Bivalirudin in Patients With Heparin-induced Thrombocytopenia,&rdquo; <i>Pharmacotherapy</i>, 2008, 28(9):1115-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/18752382/pubmed\" target=\"_blank\" id=\"18752382\">18752382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koster A, Chew D, Grundel M, et al, &ldquo;An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An <i>In Vitro</i> Study,&rdquo; <i>Anesth Analg</i>, 2003, 96(5):1316-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12707125/pubmed\" target=\"_blank\" id=\"12707125\">12707125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koster A, Chew D, Grundel M, et al, &ldquo;Bivalirudin Monitored With the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary Bypass,&rdquo; <i>Anesth Analg</i>, 2003, 96(2): 383-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17257990\"></a>Koster A, Dyke CM, Aldea G, et al, &ldquo;Bivalirudin During Cardiopulmonary Bypass in Patients With Previous or Acute Heparin-Induced Thrombocytopenia and Heparin Antibodies: Results of the CHOOSE-ON Trial,&rdquo; <i>Ann Thorac Surg</i>, 2007, 83(2):572-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17257990/pubmed\" target=\"_blank\" id=\"17257990\">17257990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koster A, Spiess B, Chew DP, et al. &ldquo;Effectiveness of Bivalirudin as a Replacement for Heparin During Cardiopulmonary Bypass in Patients Undergoing Coronary Artery Bypass Grafting,&rdquo; <i>Am J Cardiol</i>, 2004, 93(3):356-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/14759391/pubmed\" target=\"_blank\" id=\"14759391\">14759391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuchulakanti P, Wolfram R, Torguson R, et al. Brachytherapy and bivalirudin evaluation study. <i>Am Heart J.</i> 2005;150(4):832-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16209990/pubmed\" target=\"_blank\" id=\"16209990\">16209990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Bittl JA, Harrington RA, et al, &ldquo;Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. REPLACE-2 Randomized Trial,&rdquo; <i>JAMA</i>, 2003, 289(7):853-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12588269/pubmed\" target=\"_blank\" id=\"12588269\">12588269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Cutlip D. Anticoagulant therapy in acute ST elevation myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 26, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Kleiman NS, Kereiakes DJ, et al, &ldquo;Long-Term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial,&rdquo; <i>JAMA</i>, 2004, 292(6):696-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/15304466/pubmed\" target=\"_blank\" id=\"15304466\">15304466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Kleiman NS, Kottke-Marchant K, et al, &ldquo;Bivalirudin With Planned or Provisional Abciximab Versus Low-Dose Heparin and Abciximab During Percutaneous Coronary Revascularization: Results of the Comparison of Abciximab Complications With Hirulog for Ischemic Events Trial (CACHET),&rdquo; <i>Am Heart J</i>, 2002, 143(5):847-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12040347/pubmed\" target=\"_blank\" id=\"12040347\">12040347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linkins L, Dans AL, Moores LK, et al, &ldquo;Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e495-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/22315270/pubmed\" target=\"_blank\" id=\"22315270\">22315270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merry AF, Raudkivi PJ, Middleton NG, et al, &ldquo;Bivalirudin Versus Heparin and Protamine in Off-Pump Coronary Artery Bypass Surgery,&rdquo; <i>Ann Thorac Surg</i>, 2004, 77:925-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/14992900/pubmed\" target=\"_blank\" id=\"14992900\">14992900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neuhaus KL, Molhoek GP, Zeymer U, et al, &ldquo;Recombinant Hirudin (Lepirudin) for the Improvement of Thrombolysis With Streptokinase in Patients With Acute Myocardial Infarction: Results of the HIT-4 Trial,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 34(4):966-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/10520777/pubmed\" target=\"_blank\" id=\"10520777\">10520777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robson R, &ldquo;The Use of Bivalirudin in Patients With Renal Impairment,&rdquo; <i>J Invasive Cardiol</i>, 2000, 12:33F-36F.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/11156732/pubmed\" target=\"_blank\" id=\"11156732\">11156732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH, Fischer GW. Heparin-induced thrombocytopenia: a comprehensive clinical review. <i>J Am Coll Cardiol</i>. 2016;67(21):2519-2532. doi: 10.1016/j.jacc.2016.02.073.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/27230048/pubmed\" target=\"_blank\" id=\"27230048\">27230048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seybert AL, Coons JC, Zerumsky K. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? <i>Pharmacotherapy. </i>2006 Feb;26(2):229-241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16466327/pubmed\" target=\"_blank\" id=\"16466327\">16466327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shammas NW, Lemke JH, Dippel EJ, et al, &ldquo;Bivalirudin in Peripheral Vascular Interventions: A Single Center Experience,&rdquo; <i>J Invasive Cardiol</i>, 2003, 15(7):401-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12840239/pubmed\" target=\"_blank\" id=\"12840239\">12840239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25002178\"></a>Shahzad A, Kemp I, Mars C, et al; for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial [published online July 5, 2014]. <i>Lancet</i>. doi: 10.1016/S0140-6736(14)60924-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/25002178/pubmed\" target=\"_blank\" id=\"25002178\">25002178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smedira NG, Dyke CM, Koster A, et al, &ldquo;Anticoagulation With Bivalirudin For Off-Pump Coronary Artery Bypass Grafting: The Results Of The EVOLUTION-OFF Study,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 2006, 131(3):686-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/16515924/pubmed\" target=\"_blank\" id=\"16515924\">16515924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24171490\"></a>Steg PG, van 't Hof A, Hamm CW, et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. <i>N Engl J Med</i>. 2013;369(23):2207-2217. doi: 10.1056/NEJMoa1311096.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/24171490/pubmed\" target=\"_blank\" id=\"24171490\">24171490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17124018\"></a>Stone GW, McLaurin BT, Cox DA, et al, &ldquo;Bivalirudin for Patients With Acute Coronary Syndromes,&rdquo; <i>N Engl J Med</i>, 2006, 355(21):2203-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/17124018/pubmed\" target=\"_blank\" id=\"17124018\">17124018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18499566\"></a>Stone GW, Witzenbichler B, Guagliumi G, et al, &ldquo;Bivalirudin During Primary PCI in Acute Myocardial Infarction,&rdquo; <i>N Engl J Med</i>, 2008, 358(21):2218-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/18499566/pubmed\" target=\"_blank\" id=\"18499566\">18499566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsu LV and Dager WE, &ldquo;Bivalirudin Dosing Adjustments for Reduced Renal Function With or Without Hemodialysis in the Management of Heparin-Induced Thrombocytopenia,&rdquo; <i>Ann Pharmacother</i>, 2011, 45(10):1185-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/21881032/pubmed\" target=\"_blank\" id=\"21881032\">21881032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26324049\"></a>Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. <i>N Engl J Med</i>. 2015;373(11):997-1009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/26324049/pubmed\" target=\"_blank\" id=\"26324049\">26324049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasquez JC, Vichiendilokkul A, Mahmood S, et al, &ldquo;Anticoagulation With Bivalirudin During Cardiopulmonary Bypass in Cardiac Surgery,&rdquo; <i>Ann Thorac Surg</i>, 2002, 74(6):2177-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bivalirudin-drug-information/abstract-text/12643418/pubmed\" target=\"_blank\" id=\"12643418\">12643418</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8792 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F141778\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F141779\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F141795\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F141781\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F141782\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F141783\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F141784\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F141758\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F141744\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F141760\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471292\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F141759\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475242\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174519\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F141750\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F141763\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F141748\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298872\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F141752\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F141754\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F141766\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16248962\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F141756\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F141747\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F141762\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323020\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F141767\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8792|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bivalirudin-patient-drug-information\" class=\"drug drug_patient\">Bivalirudin: Patient drug information</a></li></ul></div></div>","javascript":null}